SpecificationsOrganism/cell line/tissueMus musculusSexMale and femaleSequencer or array typeIllumina Sentrix MouseRef-8 24 KData formatRaw and processedExperimental factorsTRAF3-deficient splenic B lymphomas and littermate control splenocytesExperimental featuresMicroarray data of TRAF3-deficient splenic B lymphomas and littermate control splenocytesConsentNot applicableSample source locationPiscataway, New Jersey, USA

Direct link to deposited data {#s0015}
=============================

Deposited data can be found at <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE48818>.

Experimental design, materials, and methods {#s0020}
===========================================

Sample collection and preparation {#s0025}
---------------------------------

Spleens were harvested from B cell-specific TRAF3-deficient mice with B lymphomas or tumor-free littermate control mice ([Table 1](#t0005){ref-type="table"}). In the three selected TRAF3^−/−^ splenic B lymphoma samples (mouse ID: 6983-2, 7041-10, and 7060-8), B lymphoma cells are \> 70% of B cells as assessed by FACS analysis of B cell populations and Southern blot analysis of IgH gene rearrangements [@bb0005]. Spleens were separated into single cell suspensions by mechanic dissociation, and red blood cells were depleted using 1X ACK solution as described [@bb0010], [@bb0015]. The resulting splenocytes were collected for total cellular RNA extraction using TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer\'s instructions. RNA samples were purified using an RNeasy MinElute Cleanup Kit (QIAGEN, Valencia, CA). RNA concentration and quality were assessed using a NanoDrop spectrometer (NanoDrop Products, Wilmington, DE) ([Table 1](#t0005){ref-type="table"}). RNA integrity was further analyzed on an RNA Nano Chip using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), and the results are shown in [Fig. 1](#f0005){ref-type="fig"}.

Gene expression analysis {#s0030}
------------------------

The mRNA was amplified with a TotalPrep RNA amplification kit with a T7-oligo(dT) primer according to the manufacturer\'s instructions (Ambion), and microarray analysis was carried out with the Illumina Sentrix MouseRef-8 24K Array at the Burnham Institute (La Jolla, CA).

Data processing and normalization {#s0035}
---------------------------------

Results were extracted with Illumina GenomeStudio v2011.1 and exported as the sample probe profile format without background correction or normalization. This file, along with a matching control table output from GenomeStudio, was loaded into a *lumi* object in R/Bioconductor [@bb0020], [@bb0025], [@bb0030]. Gene probes were tracked using the nuID system [@bb0020]. Background correction and quantile normalization was performed using the *lumiExpresso* function. Expression data above detection limits (using the *detectionCall* function) were selected for modeling. Target data were used to extract RNA group names as factors and assembled into a model matrix. Extracted expression values, the model design, and the array weights were used to model data in the *limma* package [@bb0035]. The contrast of "B lymphoma---control" was selected and used to generate contrasts using the *eBayes* function. Finally, gene annotation was added using the *lumiMouseAll.db* and *annotate* packages. Results were selected using the *topTable* function (with n = Inf to output all contrasts) and saved as in csv format. This table was reviewed using Excel to select significantly different genes with a minimum mean fold change ([Supplemental Table 1](#ec0005){ref-type="supplementary-material"}). A volcano plot of the modeled data clearly shows large numbers of significantly different genes with an adjusted *p*-value ≤ 0.05 and a log~2~ fold change ≥ 1 ([Fig. 2](#f0010){ref-type="fig"}).

Microarray data are available from NIH GEO Accession GSE48818 and described by Edwards et al. [@bb0040].

Statistics {#s0040}
----------

Statistical analyses were performed using limma modeling (ANOVA with empirical Bayes moderation of standard errors). Adjusted *p*-values less than 0.05 with a fold-change greater than 2 are considered significant.

Discussion {#s0010}
==========

Results of the microarray analysis have identified 160 up-regulated genes and 244 down-regulated genes in TRAF3^−/−^ B lymphomas as compared to LMC spleens (2-fold up or down fold-change, adjusted *p* \< 0.05) (NCBI GEO accession number: GSE48818).

The following is the supplementary data related to this article.Supplemental Table 1.Limma-modeled gene expression comparisons between TRAF3-deficient B cells and control. Results from limma modeling and eBayes correction were output using the topTable function. ID: NuID identifier, Gene symbol and name: official gene symbol and name, logFC: log~2~ fold change comparing TRAF3-deficient B lymphocytes to control B lymphocytes, AveExpr: average expression between the two groups, t: the *t*-statistic, P.Val and adj.P.Value: uncorrected and BH corrected probabilities, B: log-odds ratio.

This study was supported by the National Institutes of Health grants RO1CA158402 (P. Xie) and 1RC1CA147187 (R. Hart).

![Quality control assay of RNAs used for microarrays. (A) Bioanalyzer output as gel images for all seven samples as identified by the Mouse ID (see [Table 1](#t0005){ref-type="table"}). (B) Bioanalyzer output as traces with RIN (RNA integrity number) shown for each sample. Results are plotted as fluorescence units \[FU\] over time \[s\].](gr1){#f0005}

![Volcano plot of *limma*-modeled microarray data. The data for all genes are plotted as log~2~ fold change versus the − log~10~ of the adjusted *p*-value. Thresholds are shown as dashed lines. Genes selected as significantly different are highlighted as blue dots. The top ten genes (sorted by adjusted *p*-value) are labeled with gene symbols. Note the prominent position of the MCC gene, which was chosen for further analysis [@bb0040].](gr2){#f0010}

###### 

RNA samples for transcriptome profiling by microarray analysis.

  Sample ID    Sample Name   Mouse ID   Genotype                     Tissue   Concentraction   O.D. 260/280   O.D. 260/230   Total volume
  ------------ ------------- ---------- ---------------------------- -------- ---------------- -------------- -------------- --------------
  GSM1185225   XP1           6983-2     TRAF3flox/flox, CD19 +/Cre   Spleen   200 ng/μl        2.09           2.01           5 μl
  GSM1185226   XP2           7041-10    TRAF3flox/flox, CD19 +/Cre   Spleen   100 ng/μl        2.08           2.08           10 μl
  GSM1185227   XP3           7060-8     TRAF3flox/flox, CD19 +/Cre   Spleen   200 ng/μl        2.09           1.83           5 μl
  GSM1185228   XP5           6983-6     TRAF3flox/flox               Spleen   100 ng/μl        2.09           2.09           10 μl
  GSM1185229   XP6           7060-5     TRAF3flox/flox               Spleen   200 ng/μl        2.07           2.39           5 μl
  GSM1185230   XP7           7060-6     TRAF3flox/flox               Spleen   200 ng/μl        2.03           2.16           5 μl
  GSM1185231   XP9           7041-9     TRAF3flox/flox               Spleen   200 ng/μl        2.08           2.01           5 μl
